返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Hosts 2017 Coronary Product Distributor Conference

[2017-06-07] 

Shanghai, China – On May 23, the 2017 Annual Coronary Product Distributor Conference was held in Shanghai headquarters of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") and about 200 people from 110 distributors all over China attended the meeting. Bo Peng, Chief Marketing Officer of MicroPort®, Dr. Qiyi Luo, Chief Technology Officer of MicroPort®, and senior management of MicroPort® Coronary Department attended the meeting.
 
During the meeting, Bo Peng delivered a speech in which he pointed out that we should follow the tendency and change accordingly. Afterwards, Dr. Qiyi Luo introduced MicroPort®'s innovative products under development, which attracted great interest from the distributors. Meanwhile, a special discussion panel about the implementation of China's "Two Invoice System" was held during the conference. Zhigang Zhang, Director of Marketing of China Medical Instrument (Group) Co., Ltd, Kun Cao, President of Shanghai Innostic Supply Chain Management Co., Ltd, Chuan Zhang, General Manager of Beijing Jiashi Weizhong Medical Device Co., Ltd, Bing Liu, General Manager of GKHT Medical Technology Co., Ltd, and Keda Xu, Vice President and Chief Operation Officer of Cardinal Health Shanghai Co., Ltd, were invited to express their own opinions regarding the challenges and opportunities the "Two Invoice System" may bring to the pharmaceutical industry and possible actions for pharma companies to consider.
 
During the dinner party on the same day, MicroPort® gave out several awards to 11 of its distributors, including Most Valuable Diamond Partner of the Year, Most Valuable Platinum Partner of the Year, Most Valuable Gold Partner of the Year, Partner of the Best Diversification of the Year, and etc.
 
During May 22, MicroPort® also hosted an outing activity with 60 distributors in attendance to enhance communications and strengthen friendship with them.
 
Lei Jiang, First Vice President of Domestic Coronary Sales & Marketing, said :" The year 2017 marks a crucial year for the development of China's medical device industry. We believe that there are boundless opportunities and there are also challenges we must strive to overcome. We are looking forward to working more closely with our distributors and build an even more successful future together."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:ARBORES™ Kyphoplastic Balloon Catheter Receives CE Mark Approval
[Next]:MicroPort® EP's Project "Cardiac Telemedicine System Based on Smart Device and Cloud" Wins 2016 Shanghai Internet of Things Innovative Product Award